High-titer retroviral packaging cells

Details High-titer retroviral packaging cells High-titer retroviral packaging cells

2007-04-26

2011-10-11

Marvich, Maria (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C435S325000, C435S455000, C536S023100, C536S023720

Reexamination Certificate

active

08034335

ABSTRACT:
The present invention relates to non-replicative recombinant retrovirus packaging cells able to grow in suspension in a serum-free medium. In particular, the present invention relates to a human embryonic 293SF-based cell line stably expressing gag and pol gene products from the murine Moloney leukemia virus (MLV) and either the feline RD114 env gene, the gibbon ape leukemia virus (GLV) env gene, or the amphotropic 4070Aenv gene. This particular combination allows the production of high titer of non-replicative retrovirus pseudotyped and prevents the recombination of plasmids. The recombinant retroviruses produced from these cells are safer and easier to produce for clinical use in gene therapy.

REFERENCES:
patent: 5834256 (1998-11-01), Finer et al.
patent: 5910434 (1999-06-01), Rigg et al.
patent: 6210922 (2001-04-01), Côté et al.
patent: 7015035 (2006-03-01), Ward et al.
patent: 2006/0270042 (2006-11-01), Caruso et al.
patent: 2005/047497 (2005-05-01), None
Ghani K. et al., 2006, “Development of Packaging Cell Lines for the Large-Scale Production of High-Titer Clinical Grade Recombinant Retroviruses.”, Molecular Therapy, vol. 13, pp. S317-S318.
Ghani K. et al., 2007, “Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.”, Gene Therapy, vol. 14, No. 24, pp. 1705-1711.
Ghani K. et al., 2009, “Efficient Human Hematopoietic Cell Transduction Using RD114-and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free Media.”, Human Gene Therapy, vol. 20, No. 9, pp. 966-974.
Chomez, P., et al. “An Overview of the MAGE Gene Family with the Identification of All Human Members of the Family”, Cancer Research, 2001, vol. 61, pp. 5544-5551. ISSN 008-5472.
Abnova Corporation Catalogue (Under Copyright, last updated, Jul. 1, 2005; online). MAGEA9 product search [retrieved on Jan. 25, 2007]. Retrieved from the Internet: <URL:http://www.abnova.com.tw/product—search/PS—search—All.asp?GS—searchbox=MAGEA9>.
Oehlrich, N., et al. “Generation of RAGE-1 and MAGE-9 Peptide-Specific Cytotoxic T-Lymphocyte Lines for Transfer in Patients with Renal Cell Carcinoma”, Int. J. Cancer, Nov. 1, 2005, vol. 117, pp. 256-264. ISSN 0020-7136.
Miller A., et al. “Construction and Properties of Retrovirus Packaging Cells Based on Gibbon Ape Leukemia Virus”, Journal of Virology, May 1991, vol. 65, No. 5, pp. 2220-2224.
Ward et al. “A Stable Murine-Based RD114 Retroviral Packaging Line Efficiently Transduces Human Hematopoietic Cells”, Molecular Therapy, Nov. 2003, vol. 8, No. 5, pp. 804-812.
Ghani K et al. “Retroviral Vector Production Using Suspension-Adapted 293GPG Cells in a 3L Acoustic Filter-Based Perfusion Bioreactor” Biotechnol Bioeng 2006; 95: 653-660.

Affiliated with

Also associated with

Rating

High-titer retroviral packaging cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High-titer retroviral packaging cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-titer retroviral packaging cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4288280